Depression and anxiety reduce quality of life in multiple sclerosis (MS),^[@R1],[@R2]^ and depression is associated with reduced persistence to disease-modifying therapy.^[@R2]^ While such adverse effects of psychiatric comorbidity are recognized in MS, the epidemiology of psychiatric comorbidity remains poorly understood.^[@R3]^

Prevalence estimates for depression (4.98%--58.9%), anxiety (1.2%--44.6%), and bipolar disorder (0%--16.2%) vary widely in the MS population.^[@R3]^ Few studies have evaluated the prevalence of schizophrenia.^[@R4][@R5][@R7]^ Most studies suggest that depression, anxiety, and bipolar disorder affect the MS population more often than the general population,^[@R4]^ but findings regarding schizophrenia conflict.^[@R3],[@R8]^ Many of the studies that evaluated the prevalence of psychiatric comorbidities were not population-based. Furthermore, comparisons to other populations have failed to use concurrent controls. Although incidence estimates are necessary to determine risk, incidence estimates for psychiatric comorbidities are even more limited than are prevalence estimates, being reported only for depression.^[@R9]^

We aimed to estimate the incidence and prevalence of psychiatric comorbidity in MS, including sex-specific estimates, and temporal trends using population-based administrative data. We compared these findings in the MS population to those observed in controls matched for age, sex, and geographic area.

METHODS {#s1}
=======

Study populations. {#s1-1}
------------------

We adopted an approach used by the Canadian Network for Observational Drug Effect Studies.^[@R10]^ Privacy regulations prevent line-level data from leaving the province of origin. Thus, we applied a common protocol to datasets from 4 Canadian provinces, British Columbia (BC), Manitoba (MB), Quebec (QC), and Nova Scotia (NS), where nearly 43% of the Canadian population resides (<http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm>; accessed April 1, 2015), then pooled the provincial estimates using meta-analyses. Provinces were selected based on the feasibility of data access. In each province, we conducted a cohort study using anonymized administrative data, which captured virtually all residents throughout the study period. Within each province, we used unique personal identification numbers to link population registries and hospital and physician claims for the years 1990 to 2010, except in BC where data extended to 2008 and 2009.^[@R11][@R12][@R13]^ Each population registry records sex, dates of birth and death, dates of health care coverage (provincial residency), and postal code. Hospital claims include dates of admission and discharge and diagnosis codes classified using the *ICD-9* or *ICD-10-CA* system. Physician claims (for inpatient and outpatient care) include the date of service and physician-assigned diagnosis classified using *ICD-9* codes.

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

We obtained ethics approval and approval to access administrative data in each province.

We identified all persons with MS as those with ≥3 hospital or physician claims for MS (*ICD-9*/*10* = 340/G39) using an administrative case definition validated in MB and NS.^[@R14],[@R15]^ We also selected a matched cohort from the general population after excluding anyone with any diagnostic codes (*ICD-9* and *-10*) for demyelinating disease. For each case, we identified up to 5 controls matched on sex, year of birth, and region of residence (full postal code or first 3 digits of postal code if full match impossible). For each person with MS, we assigned the date of their first demyelinating disease claim as the "date of diagnosis," and the same date (index date) was assigned to their matched controls.

Psychiatric comorbidity. {#s1-3}
------------------------

Administrative case definitions for depression, anxiety, bipolar disorder, and schizophrenia developed by our group and validated in MB and NS were applied to identify affected individuals in both populations (e-Methods on the *Neurology*® Web site at [Neurology.org](http://neurology.org/lookup/doi/10.1212/WNL.0000000000002174)).^[@R4],[@R16]^ Since these disorders are conceptualized as lifelong, recurrent conditions, once a person met the case definition for the selected comorbidity, he or she was considered affected in all subsequent years while alive and resident in their province. Prevalence was estimated each year using midyear population figures as the denominators. To estimate incidence, we required a 5-year run-in period before the first comorbidity claim. In the MS cohort, a comorbidity case was defined as incident if the first comorbidity claim occurred after the date of MS diagnosis, while for the matched cohort, a comorbidity case was defined as incident if the first comorbidity claim occurred after the index date assigned to their matched case. Artifactual drops in incidence may occur at the end of a study period because new cases do not have sufficient follow-up time to meet the case definition. Therefore, we report incidence and prevalence for 1995 through 2005. We used the direct method to age-standardize findings to the 2001 Canadian population (closest to the study midpoint and consistent with earlier work). We calculated 95% confidence intervals (CIs) assuming a Poisson distribution. Cell sizes \<5 were suppressed, preventing direct modeling of crude rates. Therefore, we modeled age-standardized incidence and prevalence using Poisson regression, adjusting for year and sex.^[@R17]^ This approach controls for age effects without introducing age in the model as a covariate.^[@R17]^ We report pooled incidence rates, prevalence, adjusted rate ratios, and their 95% CIs. Given that a systematic review reported heterogeneity of prevalence estimates of psychiatric comorbidity in MS,^[@R3]^ province-specific estimates were pooled using random-effects meta-analysis and we report *I*^2^ (a measure of heterogeneity) and τ^2^ (a measure of between-study variance; e-Methods). Forest plots illustrate variation in incidence and prevalence estimates across provinces, and in rate ratios for the association between comorbidity and study population.

Analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC) and using an Excel spreadsheet for meta-analyses.^[@R18]^

RESULTS {#s2}
=======

We identified 44,452 MS cases, and 220,849 matched controls (table e-1). Of the MS cases, 31,757 (71.4%) were women with a mean (SD) age at the index date of 43.8 (13.7) years.

Depression. {#s2-1}
-----------

In 2005, the crude incidence (95% CI) of depression in the MS population was 979 per 100,000 persons or 0.98% (0.81%--1.15%, figure e-1) overall (0.94%, 0.80%--1.08% in women; 1.02%, 0.78%--1.25% in men), while it was 0.72% (0.67%--0.76%) in the matched population (figure e-2). Adjusting for year and sex, the age-standardized incidence of depression was 71% higher in the MS population than in the matched population ([table 1](#T1){ref-type="table"}, [figure 1](#F1){ref-type="fig"}). The incidence of depression was higher in women than in men but was stable over time.

###### 

Depression: Adjusted associations of incidence and prevalence with the study population, sex, and time
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![Forest plots of the association of the incidence of psychiatric comorbidity with study population (multiple sclerosis vs matched)\
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In 2005, the crude prevalence of depression in the MS population was 20.1% (19.5%--20.6%, figure e-3) overall (21.8%, 21.0%--22.5% in women; 15.2%, 14.4%--16.1% in men), while it was 11.9% (11.8%--12.1%) in the matched population (figure e-4). Adjusting for year and sex, the age-standardized prevalence of depression was higher in the MS population than the matched population ([table 1](#T1){ref-type="table"}, figure e-5). The prevalence of depression was higher in women than in men and increased slightly over time.

We observed an interaction between sex and population. The incidence of depression was 26% higher among women than men with MS, but 50% higher among women than men in the matched population (table e-2). Among women, the incidence of depression was 59% higher in the MS population than in the matched population, but among men was 93% higher in the MS than in the matched population (table e-3). The findings were similar for the prevalence of depression (tables e-2 and e-3).

Anxiety disorder. {#s2-2}
-----------------

In 2005, the crude incidence of anxiety disorder in the MS population was 638 per 100,000 persons or 0.64% (0.54%--0.73%, figure e-6) overall (0.74%, 0.62%--0.86% in women; 0.33%, 0.20%--0.46% in men), while it was 0.42% (0.39%--0.45%) in the matched population (figure e-7). Adjusting for year and sex, the age-standardized incidence of anxiety disorder was 42% higher in the MS than matched population ([table 2](#T2){ref-type="table"}, [figure 1](#F1){ref-type="fig"}). The incidence of anxiety disorder was higher in women than in men and did not change over time.

###### 

Anxiety disorder: Adjusted associations of incidence and prevalence with the study population, sex, and time
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In 2005, the crude prevalence of anxiety disorder in the MS population was 8.7% (8.4%--9.1%, figure e-8) overall (10.0%, 9.6%--10.5% in women; 4.9%, 4.4%--5.4% in men), while it was 5.1% (4.9%--5.2%) in the matched population (figure e-9). Adjusting for year and sex, the age-standardized prevalence of anxiety disorder was 58% higher in the MS population than in the matched population ([table 2](#T2){ref-type="table"}, figure e-10). The prevalence of anxiety disorder was higher in women than in men and increased slightly over time (8% per year). There was no interaction between sex and study population for incidence or prevalence.

Bipolar disorder. {#s2-3}
-----------------

In 2005, the crude incidence of bipolar disorder in the MS population was 328 per 100,000 persons or 0.33% (0.26%--0.39%, figure e-11) overall (0.27%, 0.20%--0.34% in women; 0.47%, 0.31%--0.62% in men). Although the incidence of bipolar disorder was lower in women than in men with MS in 2005, it was higher in women (0.38%, 0.35%--0.41%) than in men (0.32%, 0.28%--0.37%) if averaged over the study period. The incidence was 0.16% (0.14%--0.18%, figure e-12) in the matched population. Adjusting for year and sex, the age-standardized incidence of bipolar disorder was 99% higher in the MS than in the matched population ([table 3](#T3){ref-type="table"}, [figure 1](#F1){ref-type="fig"}). The incidence of bipolar disorder was higher in women than in men (although this was not statistically significant) and did not change over time.

###### 

Bipolar disorder: Adjusted associations of incidence and prevalence with the study population, sex, and time
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In 2005, the crude prevalence of bipolar disorder in the MS population was 4.7% (4.4%--4.9%, figure e-13) overall (5.0%, 4.7%--5.3% in women; 3.9%, 3.5%--4.3% in men), while it was 2.3% (2.2%--2.3%, figure e-14) in the matched population. Adjusting for year and sex, the age-standardized prevalence of bipolar disorder was 2-fold higher in the MS population than in the matched population ([table 3](#T3){ref-type="table"}, figure e-15). The prevalence of bipolar disorder was higher in women than in men and increased slightly over time (8% per year). There was no interaction between sex and study population for incidence or prevalence.

Schizophrenia. {#s2-4}
--------------

In 2005, the age-standardized incidence of schizophrenia in the MS population was 0.060% (0.031%--0.080%, figure e-16) overall (0.072%, 0.036%--0.11% in women; 0.011%, 0%--0.034% in men) vs 0.018% (0.011%--0.024%, figure e-17) in the matched population (because of suppression of some cells, we could not pool crude incidence). Adjusting for year and sex, the age-standardized incidence of schizophrenia disorder was 74% higher in the MS population than in the matched population ([table 4](#T4){ref-type="table"}, [figure 1](#F1){ref-type="fig"}). The incidence of schizophrenia was lower in women than in men and the incidence declined slightly over time.

###### 

Schizophrenia: Adjusted associations of incidence and prevalence with study population, sex, and time

![](NEUROLOGY2015661785TT4)

In 2005, the crude prevalence of schizophrenia in the MS population was 1.28% (1.15%--1.41%, figure e-18) overall (0.89%, 0.76%--1.02% in women; 1.22%, 0.97%--1.46% in men) vs 1.03% (0.99%--1.08%, figure e-19) in the matched population. Adjusting for year and sex, the age-standardized prevalence of schizophrenia was slightly higher in the MS population than in the matched population but this did not reach statistical significance ([table 4](#T4){ref-type="table"}, figure e-20). Unlike the other conditions, the prevalence of schizophrenia was lower in women than in men. Like the other conditions, the prevalence of schizophrenia increased slightly over time (4% per year). There was no interaction between sex and study population for incidence or prevalence.

DISCUSSION {#s3}
==========

In this population-based study involving more than 250,000 Canadians, the incidence and prevalence of anxiety, bipolar disorder, depression, and schizophrenia were all higher in the MS population than in the matched population. Over time, the incidence rates of these comorbidities were stable (except for schizophrenia, which declined) while their prevalence increased slightly. In the MS and matched populations, women had a higher incidence and prevalence of depression, anxiety disorder, and bipolar disorder than men while the opposite was true for schizophrenia.

A systematic review found no prior studies that have reported the incidence of anxiety disorders, bipolar disorder, or schizophrenia in MS,^[@R3]^ making our findings unique. Two studies have reported the incidence of depression with estimates ranging from 4.0% in 1 year to 34.7% over 5 years.^[@R9],[@R19]^ These estimates are higher than ours (979 per 100,000 persons), possibly reflecting methodologic differences. The clinic-based study identified incident depression using a self-report questionnaire and a self-reported history of no depression at baseline.^[@R19]^ The second study identified depression using a single *ICD-10* code in an administrative database, a highly sensitive but less specific approach than our case definition.^[@R9]^

A meta-analysis of 8 population-based studies reported the prevalence of depression to be 23.7% (95% CI: 17.4%--30.0%),^[@R3]^ similar to our findings of 20.1%, while this same meta-analysis found a prevalence of anxiety disorder in MS of 21.9% (95% CI: 8.76%--35.0%).^[@R3]^ However, when the 3 studies that used administrative data or other medical records to identify anxiety disorder were considered,^[@R20][@R21][@R22]^ the summary estimate was 15.4% (95% CI: 0%--39.0%), closer to our estimate of 8.7%. Thus, our findings are similar to those from previous studies that have used comparable methods. For bipolar disorder, prior studies in MS have reported a lifetime prevalence ranging from 0% to 16.2%.^[@R3]^ However, the only population-based study, which found a prevalence of 5.83% in 2005, was also conducted in the province of MB, using fewer years of data; thus, similarities to the current findings (4.7%) were expected.^[@R4]^ Previous studies of the prevalence of schizophrenia are few but prevalence estimates for schizophrenia range from 0% to 7.4%,^[@R4][@R5][@R7]^ encompassing our estimate of 1.3%.

We found that the incidence of all psychiatric comorbidities studied except schizophrenia was stable over time, while prevalence increased slightly. A survey of 9,282 Americans in the general population conducted between 2001 and 2003 reported a higher lifetime prevalence of psychiatric disorders in more recent cohorts.^[@R23]^ Prevalence may increase despite stable incidence because of earlier diagnosis or improving survival. Survival has improved in the MS and general populations over time,^[@R24]^ but we did not evaluate whether diagnosis of psychiatric comorbidities is occurring at earlier ages. We also assumed that our incident cases became prevalent cases for the entire study period, consistent with the current conceptualization of each of these disorders as lifelong, recurrent conditions.

The incidence and prevalence of psychiatric comorbidity varied considerably across provinces as shown by the forest plots. Therefore, the pooled estimate is valuable, but also should be interpreted cautiously. It represents a weighted average of the provincial estimates, but it is clear that there are differences (beyond chance variation) between provinces. The pooled random-effects estimate is the center of an estimated distribution of provincial values. Global variation in the burden of depression and anxiety is recognized in the general population,^[@R25],[@R26]^ and the Canadian Community Health survey suggested that the use of mental health services varies considerably nationwide.^[@R27]^ Some of the variation observed likely is related to the challenges of accurately distinguishing depression from anxiety based on administrative data when using 3-digit *ICD* codes.^[@R28]^ Nonetheless, our pooled estimates of the prevalence of depression, bipolar disorder, and schizophrenia are consistent with those reported for the Canadian population using other methods such as the Composite International Diagnostic Interview.^[@R29][@R30][@R31]^

The burden of all psychiatric disorders evaluated was higher in the MS population than in the matched population, and these estimates showed much less variation than the incidence and prevalence estimates. Our findings are consistent with the broader literature regarding depression, anxiety, and bipolar disorder in MS.^[@R3]^ The literature conflicts regarding the risk of schizophrenia in MS. Some studies, including ours, suggest an increased risk while others suggest no change in risk and a Swedish study reported a reduced risk.^[@R8]^ It is uncertain whether this reflects methodologic differences as several prior studies used administrative data, although differences in diagnostic coding by physicians and other factors may vary across jurisdictions.

Compared with men, women had a higher incidence and prevalence of depression, anxiety, and bipolar disorder in both populations. Worldwide, women have a higher lifetime and period prevalence of depression and anxiety,^[@R32]^ while men have a higher incidence and prevalence of schizophrenia.^[@R33]^ Thus, most of our findings are consistent with the literature in the general population regarding sex differences in psychiatric disorders. However, we found that women had a higher risk of bipolar disorder than men, which has not been reported in the MS population previously.^[@R3]^ A study using structured interviews reported that the most common bipolar disorder in MS was bipolar II disorder^[@R34]^; this may account for our findings as women and men in the general population have a similar risk of bipolar I disorder, while women have a higher incidence of bipolar II disorder.^[@R35]^ We also found that the disparity in the incidence rates between the sexes for depression was smaller in the MS than in the matched population. Previous findings have been inconsistent,^[@R36][@R37][@R38]^ but one population-based Canadian survey showed similar associations.^[@R38]^ This suggests that the increase in the incidence of depression conferred by MS is greater for men than for women. This finding requires replication in other population-based cohorts, but its implications for clinical management of MS are considerable. Examination of the underlying reasons, such as lower perceived levels of social support,^[@R39]^ lower self-efficacy, or fewer health-seeking behaviors among men with MS, is warranted. Longitudinal studies of depressive symptoms over the course of disease could identify periods of increased risk and potential risk factors.

Strengths of this study include its large size, population-based nature, and use of concurrent matched controls. However, limitations should be recognized. We used administrative data that are not collected for research, and lack clinical details such as clinical course and disability status, although we have validated our approaches to identifying MS cases and psychiatric comorbidities previously.^[@R4],[@R16]^ Our approach only captures individuals who have sought care and have had their psychiatric conditions recognized through the health system,^[@R16]^ but this potential underascertainment applies to both the MS and comparator populations. The age at MS diagnosis was later than often reported, possibly because some prevalent cases were identified when our data began in the 1990s or when they emigrated into the province rather than when they were actually diagnosed. We reported *I*^2^ as a measure of heterogeneity, but *I*^2^ tends toward 100% when the sample size is large and precision is high,^[@R40]^ thus heterogeneity was likely overestimated.

We confirmed that psychiatric comorbidity is common in MS; the incidence and prevalence of all conditions studied was higher than in a matched population. This suggests a nonspecific effect of MS on psychiatric comorbidity; MS increases the risk of all psychiatric disorders. From a policy perspective, this implies the need for general psychiatric support rather than illness-specific strategies. While the incidence and prevalence of these conditions changed little over 10 years, their increased frequency in the MS population as compared to the matched population indicates the increased burden these conditions impose on the MS population. While women with MS face a particularly high risk of depression and anxiety, men with MS face a disproportionately greater increase in the risk of depression when they develop MS.
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